Discontinuing Qelbree (Viloxazine) 400 mg
Qelbree can be discontinued without a mandatory taper, as there is no specific FDA guidance requiring gradual dose reduction for this medication. However, general principles of psychotropic medication discontinuation in ADHD suggest that a gradual taper may be prudent to monitor for symptom return and minimize potential withdrawal effects 1.
Discontinuation Approach
Direct Discontinuation vs. Tapering
The FDA label for Qelbree does not specify a required tapering schedule, distinguishing it from medications like benzodiazepines or SSRIs that have established withdrawal syndromes 1.
General psychiatric practice guidelines recommend gradual tapering of psychotropic medications to avoid withdrawal symptoms or rebound worsening of symptoms, even when specific data are limited 2.
A reasonable tapering approach would be to reduce the dose by 10% per week (e.g., from 400 mg to 360 mg, then 320 mg, etc.), based on general principles for discontinuing psychiatric medications 3.
Alternatively, you could reduce by 100-200 mg weekly (400 mg → 200 mg → 100 mg → discontinue), which aligns with the medication's available dosage strengths and typical titration increments 1.
Monitoring During Discontinuation
Develop a specific monitoring plan before discontinuing Qelbree, as symptom return may occur at different timeframes depending on ADHD presentation 2.
Monitor for return of hyperactivity symptoms within hours to days, as these typically emerge quickly after medication discontinuation 2.
Monitor for return of inattentive symptoms over a more extended period (weeks), as these may take longer to manifest 2.
Watch for withdrawal-related symptoms including insomnia, irritability, anxiety, and mood changes, which were common adverse effects during treatment and may represent precursors to emerging problems 1.
Critical Safety Considerations
Monitor closely for emergence of suicidal thoughts and behaviors during discontinuation, as Qelbree carries a black box warning for increased suicidal ideation (0.9% in pediatrics, 1.6% in adults vs. 0.4% and 0% in placebo, respectively) 1.
Assess for precursor symptoms including insomnia, irritability, depressed mood, anxiety, agitation, and impulsive behavior during the discontinuation period 1.
Instruct family members or caregivers to monitor for suicidal ideation or behavior and report immediately to the healthcare provider 1.
Cardiovascular Monitoring
Reassess blood pressure and heart rate during the discontinuation process, as Qelbree causes increases in both parameters that should normalize after discontinuation 1.
In adults, 29% experienced ≥20 bpm heart rate increases and 13% had ≥15 mmHg diastolic blood pressure increases during treatment 1.
Check vital signs at the midpoint of your taper and after complete discontinuation to ensure normalization 1.
Common Pitfalls to Avoid
Do not abruptly discontinue in patients with severe or unstable psychiatric symptoms, as this may lead to rapid symptom return without adequate monitoring 2.
Avoid discontinuing during high-stress periods (e.g., start of school year, major life transitions) when ADHD symptom control is most critical 2.
Do not assume immediate symptom return means treatment failure—some patients may experience temporary rebound that stabilizes over time 2.
Special Circumstances
If discontinuing due to adverse effects (occurred in 9% of adults and 3% of pediatric patients), you may discontinue more rapidly while maintaining close monitoring 1, 4.
If the patient is on concomitant psychostimulants, consider whether to discontinue Qelbree first or adjust both medications, as combination therapy has shown efficacy in recent trials 5.